|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Phenotypic Correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression
1 Genetic Therapy, Inc., Gaithersburg, Maryland
2 Novartis Institute for Biomedical Research, Summit, New Jersey
Hyperglycemia of diabetes is caused in part by perturbation of hepatic glucose metabolism. Hepatic glucokinase (GK) is an important regulator of glucose storage and disposal in the liver. GK levels are lowered in patients with maturity-onset diabetes of the young and in some diabetic animal models. Here, we explored the adenoviral vector–mediated overexpression of GK in a diet-induced murine model of type 2 diabetes as a treatment for diabetes. Diabetic mice were treated by intravenous administration with an E1/E2a/E3-deleted adenoviral vector encoding human hepatic GK (Av3hGK). Two weeks posttreatment, the Av3hGK-treated diabetic mice displayed normalized fasting blood glucose levels (95 ± 4.8 mg/dl; P < 0.001) when compared with Av3Null (135 ± 5.9 mg/dl), an analogous vector lacking a transgene, and vehicle-treated diabetic mice (134 ± 8 mg/dl). GK treatment also resulted in lowered insulin levels (632 ± 399 pg/ml; P < 0.01) compared with the control groups (Av3Null, 1,803 ± 291 pg/ml; vehicle, 1,861 ± 392 pg/ml), and the glucose tolerance of the Av3hGK-treated diabetic mice was normalized. No significant increase in plasma or hepatic triglycerides, or plasma free fatty acids was observed in the Av3hGK-treated mice. These data suggest that overexpression of GK may have a therapeutic potential for the treatment of type 2 diabetes.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Yang, D. M. Wilcox, D. L. Haasch, P. M. Jung, P. T. Nguyen, M. J. Voorbach, S. Doktor, S. Brodjian, E. N. Bush, E. Lin, et al. Liver-specific Knockdown of JNK1 Up-regulates Proliferator-activated Receptor {gamma} Coactivator 1beta and Increases Plasma Triglyceride despite Reduced Glucose and Insulin Levels in Diet-induced Obese Mice J. Biol. Chem., August 3, 2007; 282(31): 22765 - 22774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Pino, K.-A. Kim, K. D. Shelton, J. Lindner, S. Odili, C. Li, H. W. Collins, M. Shiota, F. M. Matschinsky, and M. A. Magnuson Glucokinase Thermolability and Hepatic Regulatory Protein Binding Are Essential Factors for Predicting the Blood Glucose Phenotype of Missense Mutations J. Biol. Chem., May 4, 2007; 282(18): 13906 - 13916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Graham, K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia, S. T. Crooke, and R. M. Crooke Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice J. Lipid Res., April 1, 2007; 48(4): 763 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Watts, V. P. Manchem, T. A. Leedom, A. L. Rivard, R. A. McKay, D. Bao, T. Neroladakis, B. P. Monia, D. M. Bodenmiller, J. X.-C. Cao, et al. Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism Diabetes, June 1, 2005; 54(6): 1846 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Crooke, M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J. Lipid Res., May 1, 2005; 46(5): 872 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Brocklehurst, V. A. Payne, R. A. Davies, D. Carroll, H. L. Vertigan, H. J. Wightman, S. Aiston, I. D. Waddell, B. Leighton, M. P. Coghlan, et al. Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule Glucokinase Activators Diabetes, March 1, 2004; 53(3): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oishi, K. Miyazaki, K. Kadota, R. Kikuno, T. Nagase, G.-i. Atsumi, N. Ohkura, T. Azama, M. Mesaki, S. Yukimasa, et al. Genome-wide Expression Analysis of Mouse Liver Reveals CLOCK-regulated Circadian Output Genes J. Biol. Chem., October 17, 2003; 278(42): 41519 - 41527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Gloyn, K. Noordam, M. A.A.P. Willemsen, S. Ellard, W. W.K. Lam, I. W. Campbell, P. Midgley, C. Shiota, C. Buettger, M. A. Magnuson, et al. Insights Into the Biochemical and Genetic Basis of Glucokinase Activation From Naturally Occurring Hypoglycemia Mutations Diabetes, September 1, 2003; 52(9): 2433 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Grimsby, R. Sarabu, W. L. Corbett, N.-E. Haynes, F. T. Bizzarro, J. W. Coffey, K. R. Guertin, D. W. Hilliard, R. F. Kester, P. E. Mahaney, et al. Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy Science, July 18, 2003; 301(5631): 370 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Su, C. L. Cioffi, S. Stefansson, N. Mittereder, M. Garay, D. Hreniuk, and G. Liau Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1429 - H1440. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |